Published in N Engl J Med on June 02, 2005
Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol (2010) 1.81
Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis (2013) 1.68
Recent advances in transthyretin amyloidosis therapy. Transl Neurodegener (2014) 1.07
Why are some amyloidoses systemic? Does hepatic "chaperoning at a distance" prevent cardiac deposition in a transgenic model of human senile systemic (transthyretin) amyloidosis? FASEB J (2012) 0.96
Serum transthyretin levels in senile systemic amyloidosis: effects of age, gender and ethnicity. Amyloid (2008) 0.87
Recent advances in the treatment of familial amyloid polyneuropathy. Ther Adv Neurol Disord (2013) 0.84
Gene expression profile in hereditary transthyretin amyloidosis: differences in targeted and source organs. Amyloid (2014) 0.84
Current and future treatment of amyloid diseases. J Intern Med (2016) 0.83
Endoplasmic Reticulum Proteostasis Influences the Oligomeric State of an Amyloidogenic Protein Secreted from Mammalian Cells. Cell Chem Biol (2016) 0.79
Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out. IUBMB Life (2015) 0.78
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis. Neurol Ther (2016) 0.77
The pathological and biochemical identification of possible seed-lesions of transmitted transthyretin amyloidosis after domino liver transplantation. J Pathol Clin Res (2016) 0.75
Transthyretin Val30Met mutation in an African American with cardiac amyloidosis. Congest Heart Fail (2010) 0.75
Iatrogenic amyloid polyneuropathy after domino liver transplantation. World J Hepatol (2017) 0.75
Transthyretin Amyloidosis: Chaperone Concentration Changes and Increased Proteolysis in the Pathway to Disease. PLoS One (2015) 0.75
Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation (2017) 0.75
NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity (2004) 13.55
Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med (2006) 6.17
Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol (2005) 5.64
Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med (2009) 5.19
Natural history and outcome in systemic AA amyloidosis. N Engl J Med (2007) 4.54
Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med (2002) 4.47
T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging (2013) 4.21
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med (2013) 3.97
Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med (2003) 3.86
Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging (2013) 3.53
Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med (2007) 3.38
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol (2007) 3.12
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol (2003) 2.74
Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl (2007) 2.59
Association of mutations in the NALP3/CIAS1/PYPAF1 gene with a broad phenotype including recurrent fever, cold sensitivity, sensorineural deafness, and AA amyloidosis. Arthritis Rheum (2002) 2.58
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood (2013) 2.38
In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med (2009) 2.34
Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood (2009) 2.30
Infusion of pharmaceutical-grade natural human C-reactive protein is not proinflammatory in healthy adult human volunteers. Circ Res (2013) 2.26
Updates in cardiac amyloidosis: a review. J Am Heart Assoc (2012) 2.21
Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol (2010) 2.20
Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum (2002) 2.19
Adult-to-adult living donor liver transplant: UK experience. Eur J Gastroenterol Hepatol (2003) 2.05
Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson (2008) 2.01
Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res (2005) 1.91
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component. N Engl J Med (2015) 1.84
Pregnancy outcome after liver transplantation: a single-center experience of 71 pregnancies in 45 recipients. Liver Transpl (2006) 1.82
Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature (2010) 1.81
Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood (2012) 1.80
Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology (2009) 1.77
One liver, three recipients: segment IV from split-liver procedures as a source of hepatocytes for cell transplantation. Transplantation (2004) 1.62
Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum (2008) 1.61
Neonatal hemochromatosis--medical treatment vs. transplantation: the king's experience. Liver Transpl (2005) 1.60
Cardiovascular magnetic resonance measurement of myocardial extracellular volume in health and disease. Heart (2012) 1.56
Liver transplantation for propionic acidemia in children. Liver Transpl (2011) 1.56
Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood (2006) 1.54
Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum (2003) 1.51
Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology (2006) 1.51
Character and temporal evolution of apoptosis in acetaminophen-induced acute liver failure*. Crit Care Med (2013) 1.51
Liver transplantation in human immunodeficiency virus-infected patients: procoagulant, but is antithrombotic prophylaxis required? Liver Transpl (2012) 1.45
Inflammatory bowel disease and systemic AA amyloidosis. Dig Dis Sci (2013) 1.43
Failure of reactivation of hepatitis B after liver transplantation in hepatitis B surface antigen-negative, core antibody-positive recipients. Transplantation (2002) 1.39
Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica (2008) 1.38
Cardiac transplantation for amyloid heart disease: the United Kingdom experience. J Heart Lung Transplant (2004) 1.36
Systemic amyloidosis and the gastrointestinal tract. Nat Rev Gastroenterol Hepatol (2009) 1.34
Diagnostic performance of 123I-labeled serum amyloid P component scintigraphy in patients with amyloidosis. Am J Med (2006) 1.32
Human plasma fibrinogen is synthesized in the liver. Blood (2006) 1.27
Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin. N Engl J Med (2012) 1.26
Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging (2012) 1.25
Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat (2014) 1.23
Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood (2005) 1.22
Outcome in renal Al amyloidosis after chemotherapy. J Clin Oncol (2011) 1.21
Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc (2013) 1.20
AL amyloidosis associated with IgM paraproteinemia: clinical profile and treatment outcome. Blood (2008) 1.20
Hepatocyte transplantation for inherited factor VII deficiency. Transplantation (2004) 1.18
Perspectives in treatment of AL amyloidosis. Br J Haematol (2007) 1.17
The role of mitochondria in ischemia/reperfusion injury. Transplantation (2002) 1.15
Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol (2006) 1.13
Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis. Amyloid (2005) 1.13
Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol (2006) 1.12
Liver transplantation in transthyretin-related familial amyloid polyneuropathy. Curr Opin Neurol (2004) 1.11
Isolation of hepatocytes from livers from non-heart-beating donors for cell transplantation. Liver Transpl (2006) 1.10
The emerging role of interleukin-1β in autoinflammatory diseases. Arthritis Rheum (2011) 1.09
Systemic amyloidosis in England: an epidemiological study. Br J Haematol (2013) 1.08
Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol (2008) 1.07
Leukocyte infiltration and inflammatory antigen expression in cadaveric and living-donor livers before transplant. Transplantation (2003) 1.06
Hereditary auto-inflammatory disorders and biologics. Springer Semin Immunopathol (2006) 1.06
Neutrophil gelatinase--associated lipocalin predicts acute kidney injury in patients undergoing liver transplantation. Liver Transpl (2010) 1.05
Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I. Am J Pathol (2011) 1.04
Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. Br J Haematol (2002) 1.04
The role of mitochondria in ischemia/reperfusion injury in organ transplantation. Kidney Int (2004) 1.04
Structure, folding dynamics, and amyloidogenesis of D76N β2-microglobulin: roles of shear flow, hydrophobic surfaces, and α-crystallin. J Biol Chem (2013) 1.04
Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. Br J Haematol (2010) 1.04
The electrocardiographic features associated with cardiac amyloidosis of variant transthyretin isoleucine 122 type in Afro-Caribbean patients. Am Heart J (2012) 1.03
Pathogenetic mechanisms of amyloid A amyloidosis. Proc Natl Acad Sci U S A (2013) 1.01
Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol (2014) 1.01
Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther (2011) 1.00
Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev (2015) 1.00
Human hepatocyte isolation and relationship of cell viability to early graft function. Cell Transplant (2003) 1.00
Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci U S A (2009) 0.99
V122I transthyretin variant in elderly black Americans. N Engl J Med (2015) 0.99
Increased model for end-stage liver disease score at the time of liver transplant results in prolonged hospitalization and overall intensive care unit costs. Liver Transpl (2010) 0.98
Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg (2008) 0.96
A prospective study investigating the cost effectiveness of intraoperative blood salvage during liver transplantation. Transplantation (2006) 0.96
Results of split liver transplantation in children. Ann Surg (2002) 0.96
Ischemic preconditioning of cadaver donor livers protects allografts following transplantation. Transplantation (2006) 0.96
AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum (2013) 0.94
The significance of paired MEFV mutations in individuals without symptoms of familial Mediterranean fever. Eur J Hum Genet (2002) 0.93
Brief Report: whole-exome sequencing revealing somatic NLRP3 mosaicism in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheumatol (2014) 0.93
Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol (2013) 0.93
Cardiac transthyretin amyloidosis. Heart (2012) 0.93
Developments in the scientific and clinical understanding of autoinflammatory disorders. Arthritis Res Ther (2009) 0.91
Isolation, purification and flow cytometric analysis of human intrahepatic lymphocytes using an improved technique. Lab Invest (2005) 0.91
The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis (2002) 0.91
Amyloidosis. Ann Clin Biochem (2012) 0.91
Diaphragmatic hernia after liver transplantation in children: case series and review of the literature. Liver Transpl (2014) 0.90
Utility of drain fluid amylase measurement on the first postoperative day after pancreaticoduodenectomy. World J Surg (2012) 0.90